US Pharma MarketingThe post Why single biomarkers are no longer enough: a new paradigm in colorectal cancer appeared first on Clinical Trials Arena.
Why single biomarkers are no longer enough: a new paradigm in colorectal cancer
Eleni Lagkadinou, Vice President, Oncology Early Development at AbbVie, and Svetlana Kobina, Vice President, Global Medical Affairs, Oncology at AbbVie, reflect on how colorectal cancer is exposing the limits of single biomarker approaches and the need for more integrated strategies in patient selection and development. Eleni Lagkadinou, Vice President, Oncology Early Development at AbbVie, and Svetlana Kobina, Vice President, Global Medical Affairs, Oncology at AbbVie, reflect on how colorectal cancer is exposing the limits of single biomarker approaches and the need for more integrated strategies in patient selection and development. Colorectal cancer (CRC) impacts an estimated 1.9 million people worldwide…
Eleni Lagkadinou, Vice President, Oncology Early Development at AbbVie, and Svetlana Kobina, Vice President, Global Medical Affairs, Oncology at AbbVie, reflect on how colorectal cancer is exposing the limits of single biomarker approaches and the need for more integrated strategies in patient selection and development.
Source: Clinical Trials Arena